Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

First Posted Date
2018-08-06
Last Posted Date
2023-05-12
Lead Sponsor
University of Heidelberg Medical Center
Target Recruit Count
662
Registration Number
NCT03617731
Locations
🇩🇪

Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Bad Saarow, Germany

🇩🇪

Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Germany

🇩🇪

Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie, Darmstadt, Germany

and more 70 locations

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

First Posted Date
2018-07-31
Last Posted Date
2021-04-28
Lead Sponsor
Nantes University Hospital
Target Recruit Count
50
Registration Number
NCT03606577
Locations
🇫🇷

CHRU Hôpital du Haut Lévêque, Pessac, France

🇫🇷

CHRU - Hôpital de Pontchaillou, Rennes, France

🇫🇷

CH de Lyon Sud, Lyon, France

and more 9 locations

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

First Posted Date
2018-07-30
Last Posted Date
2018-07-30
Lead Sponsor
Peng Liu
Target Recruit Count
25
Registration Number
NCT03605056
Locations
🇨🇳

180 Fenglin Road, Shanghai, Shanghai, China

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

First Posted Date
2018-07-19
Last Posted Date
2018-12-19
Lead Sponsor
City of Hope Medical Center
Registration Number
NCT03591744
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

🇺🇸

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States

and more 2 locations

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

First Posted Date
2018-06-15
Last Posted Date
2019-04-25
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
6
Registration Number
NCT03558750
Locations
🇺🇸

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

First Posted Date
2018-06-14
Last Posted Date
2024-03-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
41
Registration Number
NCT03556332
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Wake Forest University (Data Collection Only), Winston-Salem, North Carolina, United States

🇺🇸

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

and more 9 locations

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

First Posted Date
2018-06-01
Last Posted Date
2024-05-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
153
Registration Number
NCT03544281
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

First Posted Date
2018-05-14
Last Posted Date
2024-07-05
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
28
Registration Number
NCT03523975
Locations
🇺🇸

City of Hope Medical center, Duarte, California, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

First Posted Date
2018-04-24
Last Posted Date
2020-07-24
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT03506802
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

First Posted Date
2018-04-18
Last Posted Date
2024-07-31
Lead Sponsor
University of Chicago
Target Recruit Count
75
Registration Number
NCT03500445
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy